Monte Rosa Therapeutics, Inc
Price
FilingsNewest: 8-K, Regulation FD disclosureOct 1 →InsidersNo open-market buys. 7 insiders sold $2.5M, 15 of 28 sales on a 10b5-1 plan.→HoldersNea 9.0%BlackRock 8.0%TCG Crossover 5.4%→Financing →PeersClosest companies: ARVN, EIKN, BHVN→
From the filings
Figures
- Revenue
- $28.7Mlast 12 months
- Net income
- −$161.1Mlast 12 months
- Operating cash flow
- −$14.7Mlast 12 months
- Cash and equivalents
- $90.1Mat the last balance sheet
- Shares outstanding
- 85.2M shareson issue